Canaccord analyst Kyle Rose raised the firm’s price target on Zimmer Biomet to $130 from $120 and keeps a Buy rating on the shares. The analyst noted they put up a solid Q4 in spite of continued macro headwinds, with OUS materially outperforming given lighter comps and procedure recovery.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet price target raised to $145 from $133 at Baird
- Zimmer Biomet price target raised to $135 from $130 at Piper Sandler
- Zimmer Biomet sees FY23 adjusted EPS $6.95-$7.15, consensus $6.98
- Zimmer Biomet reports Q4 EPS $1.88, consensus $1.83
- Zimmer Biomet Announces Fourth Quarter and Full-Year 2022 Financial Results